Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

Fig. 2

Subgroup analysis of overall response rate per RECIST v1.1 by IRC review (N = 62). IRC = Independent Review Committee, RECIST = Response Evaluation Criteria in Solid Tumors, HBV = hepatitis B virus, ECOG PS = Eastern Cooperative Oncology Group Performance Score, BCLC = Barcelona Clinic Liver Cancer, TACE = transarterial chemoembolization, HAIC = hepatic arterial infusion chemotherapy, CI = confidence interval. Macrovascular Invasion or Extrahepatic Spread included 2 macrovascular invasion only patients, 32 extrahepatic spread only patients and 5 patients had both macrovascular invasion and extrahepatic spread

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us